DURECT Corporation Announces Update on DUR-928 Development Program

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/12/2026

1. PLTR
2. SPY
3. MSFT
4. AON
5. TMUS
6. LBRX
7. BMY
8. MRK
9. TRAX
10. LDOS

Go back to DURECT Corporation Announces Update on DUR-928 Development Program

DURECT Corp (DRRX) Tops Q3 EPS by 1c; Issues Update on DUR-928 Program

October 31, 2016 4:04 PM EDT

DURECT Corp (NASDAQ: DRRX) reported Q3 EPS of ($0.06), $0.01 better than the analyst estimate of ($0.07). Revenue for the quarter came in at $37 million versus the consensus estimate of $3.72 million.

DURECT also provided an update on the DUR-928 development program including a description of data from the first cohort of a Phase 1b study with DUR-928 in patients with nonalcoholic steatohepatitis (NASH).

"We are pleased to report data from cohort one of the first patient study with DUR-928, and that a single dose provided signals of DUR-928 activity in cirrhotic and non-cirrhotic... More